The California Institute for Regenerative Medicine (CIRM) has allocated $26 million to support clinical research targeting cancers, heart conditions, and rare diseases. This investment reinforces CIRM’s commitment to advancing innovative stem cell and gene therapy treatments through all stages of clinical development.
This round of awards funds five projects within CIRM’s Clinical Program, which provides essential support for eligible projects at various stages of development. With these awards, CIRM now supports 108 clinical trials, reflecting our continued dedication to groundbreaking research and transformative therapies.
This month’s Clinical Program Awards
| Grant Title and Application Number | Principal Investigator/Institution | Award Amount |
| CLIN1-14792: Superior forward-oriented b-globin vector for treating Sickle Cell Disease | Abedi, Mehrdad — UC Davis | $4,619,455 |
| CLIN1-14825: Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) | Weiss, Yael — Mahzi Therapeutics | $4,000,000 |
| CLIN1-16244: Novel Gene Therapy Targeting Multiple Pathological Drivers of Desmoplakin Associated Arrhythmogenic Cardiomyopathy | Ascheim, Deborah D. — Rejuvenate Bio | $4,000,000 |
| CLIN2-15218: A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV Gene Therapy in Male Patients with Danon Disease | Schwartz, Jonathan — Rocket Pharmaceuticals, Inc. | $5,808,735 |
| CLIN2-16156: Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies | Emery, Rochelle – Senti Bio | $8,000,000 |
These projects represent a crucial step in improving patient outcomes and offering new hope for individuals affected by these severe health challenges.
CIRM remains committed to supporting the most promising regenerative medicine research, intending to accelerate the development of treatments and cures. We are excited to see the progress that will be made possible through these new grants and look forward to their positive impact on patients’ lives.